Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | IDE | P14735 | 1/20 | 0.40 |
| ▸ | UBE2N | P61088 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25869603 | 0.90 | PLA2G2A (0.43) | NPC1POLB | |
| SCHEMBL25869340 | 0.90 | PLA2G2A (0.43) | NPC1POLB | |
| SCHEMBL25869365 | 0.90 | PLA2G2A (0.43) | NPC1POLB | |
| SCHEMBL25869347 | 0.78 | CASR (0.54) | USP2NPC1POLB | |
| SCHEMBL26492771 | 0.75 | MAPT (0.54) | USP2LMNACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL22340717 | 0.75 | MAPT (0.54) | USP2LMNACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL29335917 | 0.75 | MAPT (0.54) | USP2LMNACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL29334834 | 0.75 | MAPT (0.54) | USP2LMNACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL20870804 | 0.73 | HRH3 (0.53) | CNR2 | |
| SCHEMBL22340925 | 0.73 | HRH3 (0.53) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | CETP, NPC1, LCAT | USP2 2151/4885LMNA 305/4885CYP1A2 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.